From Yahoo Finance: 2025-06-06 13:27:00

Regeneron Pharmaceuticals, Inc. (REGN) is trading at $605.39 with a trailing and forward P/E of 15.39 and 17.39 respectively. However, their latest earnings report showed a 3.7% revenue decline and 14% EPS drop, driven by a 26% decrease in U.S. Eylea franchise sales. The FDA’s Complete Response Letter for Eylea-HD pre-filled syringe approval has been delayed due to third-party component issues. Despite this setback, Regeneron’s pipeline is expanding with promising assets like Itepekimab and a growing RNAi pipeline through their collaboration with Alnylam. Hedge fund portfolios holding REGN decreased from 68 to 66 in the first quarter.



Read more at Yahoo Finance: Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory